Seres Therapeutics, Inc.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2016 | $43.9M | $22.4M | $21.5M | $16.9M |
| FY2017 | $-75.5M | $-80.2M | $4.7M | $17.4M |
| FY2018 | $-62.9M | $-64.8M | $1.9M | $16.6M |
| FY2019 | $-76.5M | $-77.5M | $1.0M | $8.3M |
| FY2020 | $-93.6M | $-94.2M | $591.0K | $8.8M |
| FY2021 | $6.7M | $-2.9M | $9.6M | $20.2M |
| FY2022 | $-228.8M | $-238.6M | $9.8M | $25.5M |
| FY2023 | $-117.4M | $-125.3M | $8.0M | $34.1M |
| FY2024 | $-148.6M | $-149.0M | $380.0K | $21.0M |
| FY2025 | $1.1M | $865.0K | $252.0K | $10.8M |